This report was first published by Endpoints News. To see the original version, click here
Novo Nordisk expects its sales to shrink by at least 5% this year, citing negative pricing dynamics, including its deal with the US government.
The Danish pharma said in its fourth-quarter earnings report that it expects 2026 adjusted sales to fall 5% to 13% at constant exchange rates, a bigger-than-expected decline that sank the company’s shares by more than 14% in Tuesday trading.
您已阅读16%（474字），剩余84%（2504字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。